Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of $660.89 million. The enterprise value is $727.79 million.

Market Cap	660.89M
Enterprise Value	727.79M

Important Dates

The last earnings date was Monday, November 3, 2025, after market close.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Myriad Genetics has 93.21 million shares outstanding. The number of shares has increased by 2.77% in one year.

Current Share Class	93.21M
Shares Outstanding	93.21M
Shares Change (YoY)	+2.77%
Shares Change (QoQ)	+0.65%
Owned by Insiders (%)	2.64%
Owned by Institutions (%)	92.79%
Float	85.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	226.52
PS Ratio	0.79
Forward PS	0.76
PB Ratio	1.77
P/TBV Ratio	4.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.88
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.57.

Current Ratio	2.33
Quick Ratio	1.78
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-12.07

Financial Efficiency

Return on equity (ROE) is -72.52% and return on invested capital (ROIC) is -7.03%.

Return on Equity (ROE)	-72.52%
Return on Assets (ROA)	-5.67%
Return on Invested Capital (ROIC)	-7.03%
Return on Capital Employed (ROCE)	-14.15%
Revenue Per Employee	$305,667
Profits Per Employee	-$148,333
Employee Count	2,700
Asset Turnover	0.91
Inventory Turnover	8.46

Taxes

Income Tax	-24.80M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.29% in the last 52 weeks. The beta is 1.82, so Myriad Genetics's price volatility has been higher than the market average.

Beta (5Y)	1.82
52-Week Price Change	-57.29%
50-Day Moving Average	7.42
200-Day Moving Average	6.88
Relative Strength Index (RSI)	47.95
Average Volume (20 Days)	1,131,972

Short Selling Information

The latest short interest is 7.69 million, so 8.25% of the outstanding shares have been sold short.

Short Interest	7.69M
Short Previous Month	7.16M
Short % of Shares Out	8.25%
Short % of Float	8.95%
Short Ratio (days to cover)	6.95

Income Statement

In the last 12 months, Myriad Genetics had revenue of $825.30 million and -$400.50 million in losses. Loss per share was -$4.36.

Revenue	825.30M
Gross Profit	580.70M
Operating Income	-82.10M
Pretax Income	-425.30M
Net Income	-400.50M
EBITDA	-26.20M
EBIT	-82.10M
Loss Per Share	-$4.36

Full Income Statement

Balance Sheet

The company has $145.40 million in cash and $212.30 million in debt, giving a net cash position of -$66.90 million or -$0.72 per share.

Cash & Cash Equivalents	145.40M
Total Debt	212.30M
Net Cash	-66.90M
Net Cash Per Share	-$0.72
Equity (Book Value)	372.80M
Book Value Per Share	4.00
Working Capital	196.80M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$2.20 million and capital expenditures -$14.50 million, giving a free cash flow of -$16.70 million.

Operating Cash Flow	-2.20M
Capital Expenditures	-14.50M
Free Cash Flow	-16.70M
FCF Per Share	-$0.18

Full Cash Flow Statement

Margins

Gross margin is 70.36%, with operating and profit margins of -9.95% and -48.53%.

Gross Margin	70.36%
Operating Margin	-9.95%
Pretax Margin	-51.53%
Profit Margin	-48.53%
EBITDA Margin	-3.17%
EBIT Margin	-9.95%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.77%
Shareholder Yield	-2.77%
Earnings Yield	-60.60%
FCF Yield	-2.53%

Dividend Details

Analyst Forecast

The average price target for Myriad Genetics is $12.58, which is 77.43% higher than the current price. The consensus rating is "Hold".

Price Target	$12.58
Price Target Difference	77.43%
Analyst Consensus	Hold
Analyst Count	13
Revenue Growth Forecast (5Y)	3.63%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.

Last Split Date	Mar 26, 2009
Split Type	Forward
Split Ratio	2:1

Scores

Myriad Genetics has an Altman Z-Score of 0.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.58
Piotroski F-Score	4